Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Trial Profile

A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AB 101 Artiva Biotherapeutics (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Lupus nephritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Atriva Therapeutics

Most Recent Events

  • 11 Jun 2025 Planned End Date changed from 1 Oct 2026 to 1 Aug 2027.
  • 11 Jun 2025 Planned primary completion date changed from 1 Oct 2026 to 1 Aug 2027.
  • 29 Aug 2024 According to an Artiva Biotherapeutics media release, the company expect to report initial data on autoimmune indications from at least one of the Phase 1/1b trial or the basket IIT in the first half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top